Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner on the deal. Baker McKenzie advised Xbrane Biopharma.
Xbrane Biopharma AB successfully carried out a directed share issue of approximately SEK 200 million at a subscription price of SEK 68.50 per share.
The subscription price was determined through an accelerated book-building procedure. A number of Swedish and international institutional investors, including Swedbank Robur Fonder, TIN Fonder, Andra AP-fonden and Lancelot Asset Management have subscribed for shares in the Directed Share Issue.
The board of directors of the Company have, pursuant to the authorization granted by the extraordinary general meeting on 22 September 2020, resolved on the Directed Share Issue of 2,919,708 new shares at a subscription price of SEK 68.50 per share. Through the Directed Share Issue the Company will receive gross proceeds of approximately SEK 200 million before transaction related costs. The purpose of the Directed Share Issue and the reason for the deviation from the shareholders’ preferential rights is to be able to carry out a capital raise in a timely and cost-effective manner, whilst also further diversifying and strengthening the Company’s shareholder base. The board of directors’ assessment is that the subscription price in the Directed Share Issue is in accordance with market conditions, since it has been determined through an accelerated book-building procedure.
Vinge’s team has consisted of Jesper Schönbeck (Picture), Linnéa Sellström, Anders Sundin Lundberg and Lisa Malmborg.
Baker McKenzie’s team consisted of Joakim Falkner, Johanna Flink, Olof Larsson and Ian Gulam.
Involved fees earner: Joakim Falkner – Baker McKenzie; Johanna Flink – Baker McKenzie; Ian Gulam – Baker McKenzie; Olof Larsson – Baker McKenzie; Anders Sundin Lundberg – Vinge; Lisa Malmborg – Vinge; Jesper Schönbeck – Vinge; Linnéa Sellström – Vinge;